Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-12-21
2011-10-25
Berch, Mark (Department: 1622)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S263230, C514S263240, C514S263340, C514S263350, C514S263360, C544S267000, C544S268000, C544S269000, C544S270000, C544S271000, C544S272000, C544S273000
Reexamination Certificate
active
08044061
ABSTRACT:
Disclosed are novel compounds of the general formula (Ia), and pharmaceutically acceptable salts, isomers, diastereomers or enantiomers thereofand their use as medicines, for example in the treatment of dopamine-related movement disorders.
REFERENCES:
patent: 5484920 (1996-01-01), Suzuki et al.
patent: 5587378 (1996-12-01), Suzuki et al.
patent: 5703085 (1997-12-01), Suzuki et al.
patent: 2006/0205711 (2006-09-01), Himmelsbach et al.
patent: 1171442 (2005-07-01), None
patent: WO 02/064598 (2002-08-01), None
patent: WO 2004/014916 (2004-02-01), None
patent: WO/2004/092173 (2004-10-01), None
patent: WO/2004/092177 (2004-10-01), None
patent: WO/2005/097140 (2005-10-01), None
patent: WO 2006/091896 (2006-08-01), None
patent: WO 2006/091897 (2006-08-01), None
patent: WO 2006/091898 (2006-08-01), None
patent: WO 2006/091936 (2006-08-01), None
Baraldi, et al., “Current Developments of A2A Adenosine Receptor Antagonists”, Current Medicinal Chemistry, 2, pp. 707-722, 1995.
Burbiel et al., “Microwave-assisted ring closure reactions: Synthesis of 8-substituted xanthine derivatives and related pyrimido- and diazepinopurinediones”, Beilstein J. Org. Chem., 2, pp. 20-25, 2006.
Cacciara et al., “Medicinal Chemistry of A2A adenosine receptor antagonists”, Current Topics in Medicinal Chemistry, vol. 3, pp. 403-411, 2003.
Del Giudice et al., “(E)1-(Heterocyclyl or cyclohexyl)-2[1,3,7-trisubstituted (xanthin-8-yl)] ethenes as A2a adenosine receptor antagonists”, Eur J Med Chem, 31, pp. 59-63, 1996.
Drabczynska et al., “N9-benzyl-substituted 1,3-dimethyl and 1,3-dipropyl-pyrimido[2,1-f]purinediones: syntehsis and structure-activity relationships at adenosine A1 and A2A receptors”, Bioorg. Med. Chem., 15, pp. 5003-5017, 2007.
Drabczynska et al., “Phenylethyl-substituted pyrimido[2,1-f]purinediones and related compounds: Structure-activity relationships as adenosine A1 and A2A receptor ligands”, Bioorg. Med. Chem., 15, pp. 6956-6974, 2007.
Hauser et al., “Randomized trial of the adenosine A2A receptor antagonist istradefylline in advanced PD”, Neurology, 61, pp. 297-303, Aug. 2003.
Hockemeyer et al., “Multigram-Scale Syntheses, Stability, and Photoreactions of A2A Adenosine Receptor Antagonists with 8-Styrylxanthine Structure: Potential Drugs for Parkinson's Disease”, J. Org. Chem., vol. 69, No. 10, pp. 308-318, 2004.
Jacobsen et al., “Adenosine Receptors: Pharmacology, Structure-Activity Relationships, and Therapeutic Potential”, J. Med. Chem., vol. 35, No. 3, pp. 407-422, 1992.
Kiec-Konowicz et al., “New developments in A1 and A2 adenosine receptor antagonists”, Pure Appl. Chem., vol. 73, No. 9, pp. 1411-1420, 2001.
Knutsen et al., “KW-6002”, Curr. Opinion Invest Drugs, vol. 2, No. 5, pp. 668-673, 2001.
Müller et al., “1,8-Disubstituted xanthine derivatives: synthesis of potent A2B-selective adenosine receptor antagonists”, J. Med. Chem., 45, pp. 1500-1510, 2002.
Müller et al., “A new versatile synthesis of xanthines with variable substituents in the 1-, 3-, 7-, and 8-positions”, Synthesis, pp. 1295-1299, 1995.
Müller et al., “Adenosine receptors and their modulators”, Pharm. Acta. Helv., 68, pp. 77-111, 1993.
Müller et al., “Aza-analogs of 8-styrylxanthines as A2A-adenosine receptor antagonists”, Arch. Pharm. Pharm. Med. Chem., 330, pp. 181-189, 1997.
Müller et al., “Configurationally stable analogs of styrylxanthines as A2A adenosine receptor antagonists”, Eur. J. Med. Chem., 32, pp. 709-719, 1997.
Müller et al., “Effect of trifluoromethyl- and other substituents on activity of xanthines at adenosine receptors”, J. Med. Chem., 36, pp. 2639-2644, 1993.
Müller et al., “Pyrimidin-8-on[2,1-f]theophylline-9-alkylcarboxylic acids amides as A1 and A2A adenosine receptor ligands”, Il Farmaco, 58, pp. 439-444, 2003.
Müller et al., “Syntheses of paraxanthine and isoparaxanthine analogs (1, 7- and 1, 9-Substituted Xanthine Derivatives)”, Synthesis pp. 1428-1436, 1998.
Müller et al., “Synthesis and preliminary evaluation of new 1- and 3-[1-(2-hydroxy-3-phenoxypropyl)xanthines from 2-amino-2-oxazolines as potential A1 and A2A adenosine receptor antagonists”, Bioorg. Med. Chem., 14, pp. 2697-2719, 2006.
Müller et al., “Synthesis and properties of a new water-soluble prodrug of the adenosine A2A receptor antagonist MSX-2”, Molecules, 13, pp. 348-359, 2008.
Müller et al., “Synthesis and structure-activity relationships of deazaxanthanines—analogs of potent A1-and A2-adenosine receptor antagonists,” J. Med. Chem., 37, pp. 1526-1534, 1994.
Müller et al., “Synthesis of paraxanthine analogs (1, 7-disubstituted xanthines) and other xanthines unsubstituted at the 3-position: structure-activity relationships at adenosine receptors”, J. Med. Chem., 36, pp. 3341-3349, 1993.
Müller et al., “Synthesis and Structure-Activity Relationships of 3.7-Dimethyl-1-propargylxanthine Derivatives, A2A-Selective Adenosine Receptor Antagonists”, J. Med. Chem., 40, pp. 4396-4405, 1997.
Müller, “A2A Adenosine receptor antagonists—future drugs for Parkinson's disease?”, Drugs of the Future, 25, pp. 1043-1052, 2000.
Müller, “Synthesis and properties of 1-monosubstituted zanthines”, Synthesis pp. 125-128, 1993.
Müller, et al., “A2A-Selective Adenosine Receptor Antagonists: Development of Water-Soluble Prodrugs and a New Tritiated Radioligand”, Drug Development Research, Wiley-Liss, Inc., 45, pp. 190-197, 1998.
Müller, et al., “8(Sulfostyryl)xanthines: Water-soluble A2A-Selective Adenosine Receptor Antagonists”, Biorg. Med. Chem., 6, pp. 707-719, 1998.
Müller, et al., “Adenosine Receptor Antagonists: Structures and Potential Therapeutic Applications”, Current Pharmaceutical Design, 2, pp. 501-530, 1996.
Ongini et al., “Pharmacology of adensine A2A receptors”, Elsevier Science Ltd.,(Trend Pharmacol. Sci.), vol. 17, pp. 364-372, 1996.
Ongini, “Selective adenosine A2A receptor antagonists”, Il Farmaco, 56, pp. 87-90, 2001.
Sauer et al., “Water-Soluble Phosphate Prodrugs of 1-Propargyl-8-styrylxanthine Derivatives, A2A-Selective Adenosine Receptor Antagonists”, J. Med. Chem, 43, pp. 440-448, 2000.
Shimada et al., “Adenosine A2A antagonists with potent anti-cataleptic activity”, Bioorganic & Medicinal Chemistry Letters, vol. 7, No. 18, pp. 2349-2352, 1997.
Shimada et al., “(E)-1,3-Dialkyl-7-methyl-8-(3,4,5-trimethoxy-styryl)xanthines: Potent and Selective Adenosine A2 Antagonists”, J. Med. Chem., 35, pp. 2342-2345, 1992.
Vu, “Recent advances in the design and optimization of adenosine A2A receptor antagonists”, Current Opinion Drug Discovery & Development, vol. 8, No. 4, pp. 458-468, 2005.
Weiss, et al., “Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson's disease”, Neurology 61 (Suppl 6), pp. S101-S106, Dec. 2003.
Williams, “Purinergic Neurotransmission”, Neuropsychopharmacology: The Fifth Generation of Progress, pp. 191-206, 2002.
Burbiel Joachim C.
Hockemeyer Jörg
Müller Christa E.
Tzvetkov Nikolay T.
Berch Mark
Harness & Dickey & Pierce P.L.C.
Rakers Leanne M.
UCB Pharma GmbH
LandOfFree
8-alkynylxanthines and derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 8-alkynylxanthines and derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 8-alkynylxanthines and derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4270175